Jason Ehrlich, MD, PHD
Ophthalmology · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ehrlich’s office at (650) 723-6995 to ask if they take your plan before you enroll.
California Medical Board record
Licence A92211 · Current
Licensed to practise in California · since 2005 · expires 2028-10-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$49 in 2023
| 2023 | 1 | 1 | None | $49 |
| 2019 | 1 | 1 | $2,518 | $2,518 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Research & Development | Whitestar Phaco Handpiece | $49 | 1 payment
|
See the published payment
| Janssen Research & Development | Meals · 2023-03-16 | Whitestar Phaco Handpiece | $49 |
See earlier years (2019)
2019: $2,518
| F. Hoffmann-La Roche AG | Lucentis | $2,518 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · Intravitreal Ranibizumab Or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema Combination With Laser Photocoagulation for Diabetic Macular Edema · 2020 | This clinician | $9,999 |
| F. Hoffmann-La Roche AG · Stairway Simultaneous Blockade of Angiopoietin-2 and Vegf-A With the Bispecific Antibody Ro6867461 Rg7716 for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration · 2020 | This clinician | $2,366 |
| F. Hoffmann-La Roche AG · A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus, A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus · 2020 | This clinician | $1,942 |
Professional record
- NPI
- 1447446752
- Licence
- CA A92211California A92211: Current · expires 2028-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-09-20
- NPI last updated
- 2008-07-29
This is when the NPI record was last certified, not a medical board exam.